natgillin/translations-raw huggingface dataset:
During the initial 18 weeks the insulin dose was kept stable, but was adjusted to achieve a FPG &lt; 110 mg/dl in the following 60 weeks.
Tijekom početnih 18 tjedana doza inzulina je bila stabilna, ali se prilagođavala u cilju postizanja razine glukoze natašte (FPG) &lt; 110 mg/dl u slijedećih 60 tjedana.
During the initial 18 weeks the insulin dose was kept stable, but was adjusted to achieve a FPG &lt; 110 mg/dl in the following 60 weeks.
Tijekom početnih 18 tjedana doza inzulina je bila stabilna, ali se prilagođavala u cilju postizanja razine glukoze natašte (FPG) &lt; 110 mg/dl u narednih 60 tjedana.
During the open-label extension, statistically significant (p &lt; 0.05) improvements from baseline were observed in the diarrhoea and indigestion domains, with a trend of improvement in the constipation domain.
Tijekom otvorenog nastavka ispitivanja statistički značajna poboljšanja (p &lt; 0,05) u odnosu na početnu vrijednost primijećena su u području proljeva i probavnih tegoba, uz trend poboljšanja u području konstipacije.
During the treatment period, rare clinical effects ( &gt; 0.01% to &lt; 0.1%) have been reported: hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence, down-regulation associated signs (decrease in testicle size, reduced activity).
Tokom tretmana su zamijećeni rijetki klinički efekti ( &gt; 0,01% do &lt; 0,1%); promjene na dlaci (npr. gubitak i modifikacija dlake, alopecija) urinarna inkontinencija, i opći simptomi pada (smanjenje obujma testisa, reducirana aktivnost).
During the treatment period, rare clinical effects ( &gt; 0.01% to &lt; 0.1%) have been reported: hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence, down-regulation associated signs (e.g. decrease in testicle size, reduced activity).
Tokom tretmana su zamijećeni rijetki klinički efekti ( &gt; 0,01% do &lt; 0,1%); promjene na dlaci (npr. gubitak i modifikacija dlake, alopecija) urinarna inkontinencija, i opći simptomi pada (smanjenje obujma testisa, reducirana aktivnost).
During the treatment period, rare clinical effects ( &gt; 0.01% to &lt; 0.1%) have been reported: hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence, down-regulation associated signs (e.g. decrease in testicle size, reduced activity).
U vrlo rijetkim slučajevima ( &gt; 0.01% do &lt; 0.1%) su bile prijavljene promijene na dlaci (npr. gubitak i modifikacija dlake, alopecija,), urinarna inkontinencija, opadajući znaci (umanjeni testisi, smanjena aktivnost).
During treatment with Integrilin in this study, minor bleeding was a very common complication ( &gt; 1/10, or 13.1% for Integrilin versus 7.6% for placebo).
Tijekom liječenja INTEGRILINom u ovom ispitivanju manje krvarenje je bilo vrlo česta komplikacija ( &gt; 1/10 ili 13,1 % uz INTEGRILIN u odnosu na 7,6 % uz placebo).
During treatment with nitric oxide, the NO2 concentration should be &lt; 0.5 ppm in the nitric oxide dose range &lt; 20 ppm.
Tijekom liječenja dušikovim (II) oksidom, koncentracija NO2 mora biti &lt; 0,5 ppm u rasponu doze dušikovog (II) oksida &lt; 20 ppm.
DUTREBIS should not be given in patients with a creatinine clearance of &lt; 50 ml/min.
DUTREBIS se ne smije davati bolesnicima s klirensom kreatinina od &lt; 50 ml/min.
Dysgeusia (G3/4: 0.6%); Peripheral sensory neuropathy (G3/4: &lt; 0.1%)
disgeusija (G3/4: 0,6%),
Dysgeusia (G3/4: &lt; 1%); Paraesthesia (G3/4: &lt; 1%)
disgeuzija (G3/4: &lt; 1%), parestezija (G3/4: &lt; 1%)
Dysgeusia (G3/4: &lt; 1%); Paraesthesia (G3/4: &lt; 1%)
disgeuzija (G3/4: &lt; 1%); parestezija (G3/4: &lt; 1%)
Dysgeusia (G3/4: &lt; 1%); Paraesthesia (G3/4: &lt; 1%)
dizgeusija (G3/4: &lt; 1%); parestezija (G3/4: &lt; 1%)
Dyspnoea (G3/4: 1%); Cough (G3/4: &lt; 1%); Epistaxis (G3/4: &lt; 1%)
dispneja (G3/4: 1%), kašalj (G3/4: &lt; 1%), epistaksa (G3/4: &lt; 1%)
Dyspnoea (G3/4: 1%); Cough (G3/4: &lt; 1%); Epistaxis (G3/4: &lt; 1%)
dispneja (G3/4: 1%); kašalj (G3/4: &lt; 1%); epistaksa (G3/4: &lt; 1%)
E Haematocrit values &gt; 55 % were reported in 1.3 % of the subjects treated with dapagliflozin 10 mg versus
E U 1,3 % ispitanika liječenih sa 10 mg dapagliflozina zabilježene su vrijednosti hematokrita &gt; 55 % u usporedbi sa 0,4
E. coli J5 inactivated &gt; 50 RED60 (Rabbit effective dose in 60% of the animals (serology)).
E. coli J5 inaktivirana &gt; 50 RED60 (djelotvorna doza u kunića, u 60% životinja (serološki nalaz)).
E/C/F/TAF met the non-inferiority criteria in achieving HIV-1 RNA &lt; 50 copies/mL when compared to E/C/F/TDF.
U usporedbi s E/C/F/TDF-om, E/C/F/TAF je ispunio kriterije neinferiornosti u postizanju vrijednosti HIV-1 RNK &lt; 50 kopija/ml.
Eckert &amp; Ziegler EURO-PET Berlin GmbH - BERLIN Max-Planck-Strasse 4
Eckert &amp; Ziegler EURO-PET Berlin GmbH – BERLIN Max-Planck-Strasse 4
Eckert &amp; Ziegler EURO-PET Berlin GmbH, Germany
Eckert &amp; Ziegler EURO-PET Berlin GmbH, Njemačka
Eckert &amp; Ziegler EURO-PET Koeln/Bonn GmbH, Germany
Eckert &amp; Ziegler EURO-PET Koeln/Bonn GmbH, Njemačka
Eckert &amp; Ziegler EURO-PET Warszawa Sp. z o.o. - WARSAW ul.
Eckert &amp; Ziegler EURO-PET Warszawa Sp. z o.o. – WARSAW ul.
Eckert &amp; Ziegler EURO-PET Warszawa Sp. z o.o., Poland
Eckert &amp; Ziegler EURO-PET Warszawa Sp. z o.o., Poljska
Eckert &amp; Ziegler Radiopharma GmbH Branch Braunschweig
Eckert &amp; Ziegler Radiopharma GmbH Podružnica Braunschweig
eculizumab rate,
P &lt; 0,0001
Edistride has not been studied in severe renal impairment (CrCl &lt; 30 ml/min or eGFR &lt; 30 ml/min/1.73 m2) or end-stage renal disease (ESRD).
Edistride nije ispitana u teškom oštećenju bubrežne funkcije (CrCl &lt; 30 ml/min ili eGFR &lt; 30 ml/min/1,73 m2) ili terminalnoj fazi bubrežne bolesti.
Edistride is not recommended for use in patients with moderate to severe renal impairment (patients with CrCl &lt; 60 ml/min or eGFR &lt; 60 ml/min/1.73 m2).
Primjena lijeka Edistride ne preporučuje se u bolesnika s umjerenim do teškim oštećenjem bubrežne funkcije (bolesnici u kojih je CrCl &lt; 60 ml/min ili eGFR &lt; 60 ml/min/1,73 m2).
Edoxaban is metabolised via hydrolysis (mediated by carboxylesterase 1), conjugation or oxidation by CYP3A4/5 ( &lt; 10%).
Edoksaban se metabolizira hidrolizom (posredovanom karboksilesterazom 1), konjugacijom ili oksidacijom CYP3A4/5 ( &lt; 10%).
Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts &lt; 50 cells/mm3, or after failure of protease inhibitor (PI)-containing regimens.
Efavirenz još nije dovoljno ispitan u bolesnika s uznapredovalom bolesti HIV-a, kao primjerice u bolesnika s brojem CD4 &lt; 50 stanica /mm3 ili nakon neuspjeha kombiniranog liječenja inhibitorima proteaze (IP).
Efavirenz has not been studied in controlled studies in patients with advanced HIV disease, namely with CD4 counts &lt; 50 cells/mm3, or in PI or NNRTI experienced patients.
Nisu provedena kontrolirana ispitivanja efavirenza u bolesnika s uznapredovalom HIV bolešću, kao što su osobe s &lt; 50 CD4 stanica/mm3, niti u bolesnika koji su već primali inhibitore proteaze ili NNRTI-je.
Efavirenz has not been studied in controlled studies in patients with advanced HIV disease, namely with CD4 counts &lt; 50 cells/mm3, or in PI or NNRTI experienced patients.
Nisu provedena kontrolirana ispitivanja efavirenza u bolesnika s uznapredovalom HIV bolešću, to jest s &lt; 50 CD4 stanica/mm3, niti u bolesnika koji su već primali inhibitore proteaze ili NNRTI-je.
Efavirenz has not been studied in controlled studies in patients with advanced HIV disease, namely with CD4 counts &lt; 50 cells/mm3, or in PI or NNRTI-experienced patients.
Nisu provedena kontrolirana ispitivanja efavirenza u bolesnika s uznapredovalom HIV bolešću, kao što su osobe s &lt; 50 CD4 stanica/mm3, niti u bolesnika koji su već primali inhibitore proteaze ili NNRTI-je.
Efavirenz is highly bound ( &gt; 99%) to human plasma proteins, predominantly albumin.
Efavirenz ima svojstvo snažnog vezivanja ( &gt; 99%) na proteine ljudske plazme, pretežno na albumin.
Effect on Co- administered Medicinal Products Cmax
Utjecaj istodobno primijenjenog lijeka na AUC lijeka na Cmax
Effects in repeated dose studies were observed only at exposures considered sufficiently in excess ( &gt; 25-, &gt; 45-, and &gt; 35-fold for mice, rats, and dogs, respectively) of the maximum human exposure of ivacaftor when administered as Orkambi, indicating little relevance to clinical use.
U ispitivanjima ponovljene doze učinci su opaženi samo pri izloženostima koje su se smatrale dovoljno većima ( &gt; 25 puta za miševe, &gt; 45 puta za štakore i &gt; 35 puta za pse) od najveće izloženosti u ljudi za ivakaftor kada se primjenjuje kao Orkambi, što ukazuje na njihov mali značaj za kliničku primjenu.
Efficacy and durability of effect were measured in the primary end-point as response over the 12-week treatment period to naloxegol as defined by &gt; 3 SBMs per week and a change from baseline of &gt; 1 SBM per week for at least 9 out of the 12 study weeks and 3 out of the last 4 weeks.
Djelotvornost i trajanje učinka mjereni su u sklopu primarne mjere ishoda kao odgovor na naloksegol tijekom 12-tjednog razdoblja liječenja, koji je definiran kao &gt; 3 spontana pražnjenja crijeva tjedno i promjena od &gt; 1 spontanog pražnjenja crijeva tjedno u odnosu na početnu vrijednost tijekom najmanje 9 od 12 tjedana ispitivanja te tijekom 3 od posljednja 4 tjedna.
Efficacy and safety data in patients with hypophosphatasia &gt; 18 years old are limited.
Ograničeni su podaci o djelotvornosti i sigurnosti u bolesnika s hipofosfatazijom starijih od 18 godina.
Efficacy and safety data in the age group 2 months to &lt; 3 years (9 patients) is limited (see section 5.1).
Podaci o djelotvornosti i sigurnosti primjene u dobnoj skupini od 2 mjeseca do &lt; 3 godine (9 bolesnika) su ograničeni (vidjeti dio 5.1).
Efficacy and safety in elderly &gt; 65 years have not been established.
Djelotvornost i sigurnost primjene u osoba starijih od 65 godina nisu ustanovljene.
Efficacy has not been established in patients with FEV1 &gt; 75% predicted.
Djelotvornost Caystona nije utvrđena u bolesnika u kojih je FEV1 bio &gt; 75% predviđene vrijednosti.
Efficacy of eluxadoline was assessed using an overall responder analyses as defined by the simultaneous improvement in the daily WAP score by ≥30% as compared to the baseline weekly average AND a reduction in the BSS to &lt; 5 on at least 50% of the days within a time interval.
Djelotvornost eluksadolina ocijenjena je primjenom cjelokupne analize bolesnika koji su odgovorili na liječenje kako je definirano simultanim poboljšanjem bodova dnevnog WAP-a za ≥30% u usporedbi s tjednim prosjekom na početku ispitivanja i smanjenjem BSS-a na &lt; 5 u najmanje 50% dana unutar određenog vremenskog razdoblja.
Efficacy of the measles, mumps, and rubella components of ProQuad was previously established in a series of double-blind controlled field trials with the monovalent vaccines manufactured by Merck &amp; Co., Inc., which demonstrated a high degree of protective efficacy.
Djelotvornost komponenti morbila, parotitisa i rubele u cjepivu ProQuad bila je prethodno ustanovljena u nizu dvostruko slijepih kontroliranih terenskih ispitivanja s monovalentnim cjepivima proizvođača Merck &amp; Co., Inc., koja su pokazala visoki stupanj zaštitne djelotvornosti.
Efficacy was not evaluated in the 14 children with CF (≥ 6 to &lt; 12 years old) and 13 adolescents with CF
Djelotvornost nije procjenjivana u 14 djece s CF (u dobi ≥ 6 do &lt; 12 godina) i
Efficib should not be used in patients with moderate or severe renal impairment (creatinine clearance &lt; 60 mL/min) (see sections 4.3 and 4.4).
Efficib se ne smije primjenjivati u bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 60 ml/min) (vidjeti dijelove 4.3 i 4.4).
eGFR ≥60 to &lt; 90 ml/min/1.73 m²
eGFR ≥60 do &lt; 90 ml/min./1,73 m²
Elbasvir and grazoprevir are extensively bound ( &gt; 99.9 % and 98.8 %, respectively) to human plasma proteins.
Elbasvir i grazoprevir se u velikoj mjeri ( &gt; 99,9% odnosno 98,8%) vezuju za proteine u plazmi ljudi.
Elderly ( &gt; 65 years)
Starije osobe ( &gt; 65 godina)
Elderly ( &gt; 60 years)
Starije osobe ( &gt; 60 godina)
Elderly ( &gt; 60 years):
Starije osobe ( &gt; 60 godina):
Elderly ( &gt; 65 years of age): Benlysta has been studied in a limited number of elderly patients.
Starije osobe (u dobi od ≥ 65 godina): Benlysta je ispitivana na ograničenom broju starijih bolesnika.
Elderly ( &gt; 65 years old)
Starije bolesnice ( &gt; 65 godina)
Elderly ( &gt; 65 years old)
Stariji (u dobi od &gt; 65 godina)
Elderly ( &gt; 65 years old)
Stariji (≥65 godina)
Elderly ( &gt; 65 years), hypertensive and diabetic patients reported diarrhoea more frequently as compared to the overall IBS-C population included in the clinical trials.
Stariji bolesnici ( &gt; 65 godina), bolesnici s hipertenzijom i dijabetesom su prijavili proljev češće nego ukupna populacija s dijagnozom IBS-C-a uključena u klinička ispitivanja.
Elderly (≥65 years old)
Stariji (u dobi od &gt; 65 godina)
Elderly patients ( &gt; 65 years of age)
Stariji bolesnici (u dobi &gt; 65 godina)
Elderly patients ( &gt; 65 years of age) or patients with multiple co-morbidities who experience a serious hypersensitivity reaction may have more severe outcomes.
U starijih bolesnika (u dobi od &gt; 65 godina) ili bolesnika s višestrukim komorbiditetom koji dobiju ozbiljnu reakciju preosjetljivosti, ishodi mogu biti teži.
Elderly patients ( &gt; 65 years old)
Stariji bolesnici ( &gt; 65 godina)
Elderly patients ( &gt; 65 years)
Starije osobe ( &gt; 65 godina)
Elderly patients ( &gt; 65 years)
Stariji bolesnici ( &gt; 65 godina)
Elderly patients ( &gt; 70 years of age)
Stariji bolesnici ( &gt; 70 godina)
Elderly patients ( &gt; 65 years old)
Stariji bolesnici ( &gt; 65 godina starosti)
Elderly patients ( &gt; 65 years)
Stariji bolesnici (≥ 65 godina)
Elderly patients (≥ 65 years old)
Stariji bolesnici ( &gt; 65 godina)
Elderly patients (≥65 years)
Stariji bolesnici ( &gt; 65 godina)
Elderly patients( &gt; 65 years)
Starije osobe ( &gt; 65 godina)
Elderly population ( &gt; 65 years)
Starija populacija ( &gt; 65 godina)
Elderly: ( &gt; 65 years) no dosage adjustment is necessary.
Stariji: ( &gt; 65 godina) nije potrebna prilagodba doze.
Elderly: The clinical experience in patients &gt; 65 years of age is very limited.
Starije osobe: Kliničko iskustvo u pacijenata starijih od 65 godina vrlo je ograničeno.
Elderly: There is no experience in patients &gt; 65 years old.
Starije osobe: Nema iskustva u bolesnika starijih od 65 godina.
Elevated liver transaminases: If elevations in liver transaminases &gt; 5 × institutional upper limit of normal (ULN) occur, bosutinib should be interrupted until recovery to ≤ 2.5×ULN and may be resumed at 400 mg once daily thereafter.
Porast jetrenih transaminaza: ako se javi porast jetrenih transaminaza &gt; 5 × institucionalne gornje granice normale (GGN), liječenje bosutinibom mora se prekinuti do oporavka na ≤ 2,5 × GGN, a može se nastaviti nakon toga s 400 mg jedanput dnevno.
Elevation ( &gt; 3xULN) of serum aspartate aminotransferase (AST) was observed in 3.1% (30/958) of patients on tolvaptan and 0.8% (4/484) patients on placebo.
Povišena ( &gt; 3xGGN) aspartat aminotransferaza (AST) u serumu opažena je u 3,1% (30/958) bolesnika na tolvaptanu i u 0,8% (4/484) bolesnika na placebu.
Elevation in LDL &gt; 1.5 x ULN to 2 x ULN occurred in 1.9% of patients in the tocilizumab group, and in 0% of the placebo group.
Povišena razina LDL-a &gt; 1,5 x do 2 x iznad gornje granice normale zabilježena je kod 1,9% bolesnika iz skupine koja je primala tocilizumab te kod 0% bolesnika iz skupine koja je primala placebo.
Elevation of AST or ALT ≥ 3 × ULN concurrent with an elevation of bilirubin &gt; 2 × ULN and alkaline phosphatase &lt; 2 × ULN
Porast vrijednosti AST-a ili ALT- a ≥ 3 x GGN istodobno uz povišenje bilirubina &gt; 2 x GGN i alkalne fosfataze &lt; 2 x GGN
Elevation of AST or ALT ≥ 3 × ULN concurrent with an elevation of bilirubin &gt; 2 × ULN and alkaline phosphatase &lt; 2 × ULN
Porast vrijednosti AST-a ili ALT- a ≥ 3 x GGN uz istodobno uz povišenje bilirubina &gt; 2 x GGN i alkalne fosfataze &lt; 2 x GGN
Elevations &gt; 5 × ULN occurred in 2.5% of patients on macitentan 10 mg versus 2% of patients on placebo.
Povišenja &gt; 5 × GGN dogodila su se u 2,5% bolesnika koji su primali macitentan 10 mg naspram 2% bolesnika koji su primali placebo.
Elevations in ALT and AST &gt; 3 × upper limit of normal (ULN) have been reported in patients receiving therapy with Esbriet.
U bolesnika koji su primali Esbriet primijećeno je povišenje razine ALT-a i AST-a &gt; 3 x iznad gornje granice normale (GGN).
Elevations in ALT and AST of Grade 3 and 4 ( &gt; 5 x ULN) have been observed in clinical studies of idelalisib.
U kliničkim ispitivanjima idelalisiba uočena su povišenja vrijednosti ALT i AST 3. i 4. stupnja ( &gt; 5 x GNN).
Elevations in ALT and/or AST &gt; 5 x ULN were managed with a dose reduction or temporary suspension of lomitapide dosing, and all patients were able to continue with study drug treatment.
Povišene vrijednosti ALT i/ili AST &gt; 5 x GGN zbrinjavane su smanjenjem doze ili privremenim prekidom doziranja lomitapida, i svi su bolesnici mogli nastaviti terapiju ispitivanim lijekom.
Elevations of ALT/AST &gt; 5 x ULN were observed in 0.7% of tocilizumab monotherapy patients and 1.4% of tocilizumab plus DMARD patients, the majority of whom were discontinued permanently from tocilizumab treatment.
Povišenje vrijednosti ALT/AST &gt; 5 x iznad gornje granice normale bilo je primijećeno u 0,7% bolesnika na monoterapiji tocilizumabom i 1,4% bolesnika na terapiji tocilizumabom i DMARD-om; u većine tih bolesnika liječenje tocilizumabom je trajno prekinuto.
Eleven (21%) patients had an increase from Baseline in QTcF value ≥30 to &lt; 60 msec and 1 (2%) patient had an increase from Baseline in QTcF value of ≥60 msec.
Jedanaest (21%) bolesnika imalo je povećanje u odnosu na početne vrijednosti QTcF-intervala ≥ 30 do &lt; 60 msek, a 1 bolesnik (2%) imao je povećanje u odnosu na početne vrijednosti QTcF-intervala od ≥ 60 msek.
Eleven percent of children (5/46) treated for 24 weeks and 13 % of children (6/48) treated for 48 weeks were observed to have a decrease from pre-treatment baseline &gt; 30 height-for-age percentiles to the end of the 5 year long-term follow-up.
U jedanaest posto djece (5/46) liječene tijekom 24 tjedna i 13% djece (6/48) liječene 48 tjedana zabilježeno je smanjenje visine za percentile godina u odnosu na početak ispitivanja prije liječenja &gt; 30 do kraja petogodišnjeg dugotrajnog praćenja.
Eleven percent of subjects (5/46) treated for 24 weeks and 13 % of subjects (6/48) treated for 48 weeks were observed to have a decrease from pre-treatment baseline of &gt; 30 height-for-age percentiles to the end of the 5 year long-term follow-up.
Na kraju 5-godišnjeg dugotrajnog praćenja, u 11% djece (5/46) liječene 24 tjedna te 13% djece (6/48) liječene 48 tjedana primijećen je pad za &gt; 30 percentila na percentilnoj krivulji rasta za dob u odnosu na vrijednost prije početka liječenja.
Eli Lilly &amp; Company Ltd Elanco Animal Health Lilly House
Eli Lilly &amp; Company Ltd Elanco Animal Health Lilly House Priestley Road
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV- RNA polymerase chain reaction assay (PCR) ( &gt; 30 IU/mL), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Bolesnici pogodni za ova ispitivanja imali su kronični hepatitis C potvrđen pozitivnim nalazom HCV-RNK pomoću testa lančane reakcije polimerazom (PCR) ( &gt; 30 IU/ml), nalazom biopsije jetre koji je odgovarao patohistološkoj dijagnozi kroničnog hepatitisa bez nekog drugog mogućeg uzroka kroničnog hepatitisa i odstupanjem od normalnih vrijednosti ALT-a u serumu.
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction (PCR) assay ( &gt; 30 IU/ml), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Bolesnici pogodni za ova ispitivanja imali su kronični hepatitis C potvrđen pozitivnim nalazom HCV-RNK pomoću testa lančane reakcije polimerazom (PCR) ( &gt; 30 IU/ml), nalazom biopsije jetre koji odgovara histološkoj dijagnozi kroničnog hepatitisa koji nije mogao biti uzrokovan drugim čimbenikom te odstupanjem od normalne vrijednosti ALT-a u serumu.
Eligible patients had epithelial ovarian, fallopian tube or primary peritoneal cancer that progressed within &lt; 6 months of previous platinum therapy consisting of a minimum of 4 platinum therapy cycles.
Bolesnice koje su se mogle uključiti u ispitivanje imale su epitelni karcinom jajnika, karcinom jajovoda ili primarni peritonealni karcinom koji je progredirao unutar &lt; 6 mjeseci od prethodne terapije platinom, koja je obuhvaćala najmanje 4 ciklusa terapije platinom.
Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia ( &lt; 500 cells/mm3 for 96 hours) and fever ( &gt; 38.0°C) not responding to ≥96 hours of parenteral antibacterial therapy.
Odabrani bolesnici primali su kemoterapiju zbog maligne bolesti ili su im bile presađene krvotvorne matične stanice, a imali su neutropeniju ( &lt; 500 stanica/mm3 tijekom 96 sati) i vrućicu ( &gt; 38,0°C) koje nisu odgovarale na parenteralnu antibakterijsku terapiju koja je trajala ≥96 sati.
Elimination is primarily by the renal route ( &gt; 85% of the dose following oral or intravenous administration).
Eliminacija se primarno odvija putem bubrega ( &gt; 85% doze nakon peroralne ili intravenske primjene).
Elimination through urine is negligible ( &lt; 1%).
Eliminacija putem mokraće je zanemariva ( &lt; 1%).
Elimination: Erlotinib is excreted predominantly as metabolites via the faeces ( &gt; 90%) with renal elimination accounting for only a small amount (approximately 9%) of an oral dose.
Eliminacija: Erlotinib se uglavnom izlučuje u obliku metabolita putem fecesa ( &gt; 90%), dok se manji dio peroralne doze uklanja putem bubrega (otprilike 9%).
Elimination: Valsartan shows multiexponential decay kinetics (t½α &lt; 1 h and t½ß about 9 h).
Eliminacija: Valsartan pokazuje multieksponencijalnu kinetiku raspadanja (t½α &lt; 1 h i t½ß oko 9 h).
ELISA &gt; 3.34 log2 IE50 %
ELISA &gt; 3,34 log2 IE50
ELISA &gt; 3.34 log2 IE50%*
ELISA &gt; 3,34 log2 IE50
ELISA &gt; 3.34 log2 IE50%**
ELISA &gt; 3,34 log2 IE50
Elotuzumab has not been studied in patients with moderate (TB &gt; 1.5 to 3 × ULN and any AST) or severe hepatic impairment (TB &gt; 3 × ULN and any AST) (see section 4.2).
Elotuzumab se nije ispitivao u bolesnika s umjerenim (ukupni bilirubin &gt; 1,5 do 3 × GGN i bilo koja vrijednost AST-a) ili teškim oštećenjem funkcije jetre (ukupni bilirubin &gt; 3 × GGN i bilo koja vrijednost AST-a) (vidjeti dio 4.2).
Eltrombopag is highly bound to human plasma proteins ( &gt; 99.9%), predominantly to albumin.
Eltrombopag se izrazito veže za proteine ljudske plazme ( &gt; 99,9%), prvenstveno za albumin.
Eluxadoline exists predominantly as the (S,S)-diastereomer ( &gt; 99%) and undergoes little or no chiral conversion in vivo.
Eluksadolin postoji pretežno kao (S,S)-dijastereomer ( &gt; 99%), a kiralna konverzija in vivo je minimalna ili odsutna.
Elvitegravir was non-inferior in achieving HIV-1 RNA &lt; 50 copies/mL when compared to raltegravir.
Elvitegravir je bio neinferioran u postizanju HIV-1 RNK &lt; 50 kopija/ml u usporedbi s raltegravirom.
Emetogenic chemotherapies administered included doxorubicin, cyclophosphamide ( &lt; 1500 mg/m2), ifosfamide, cisplatin, dactinomycin, carboplatin, and daunorubicin.
Primijenjene emetogene kemoterapije uključivale su doksorubicin, ciklofosfamid ( &lt; 1500 mg/m2), ifosfamid, cisplatin, daktinomicin, karboplatin i daunorubicin.